Granulox® wins Prix Galien
Mölnlycke’s haemoglobin spray Granulox® has been awarded the prestigious Prix Galien for best new medical device in Belgium.
Granulox is Mölnlycke’s innovative topical haemoglobin spray which facilitates oxygen diffusion for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
When Granulox is sprayed on a wound, highly purified haemoglobin is released. This binds with oxygen from the environment and diffuses through the exudate to supply oxygen to the base of the wound, supporting wound healing and improving patient outcomes.
Studies report that using Granulox results in shorter healing time, reduced pain scores and total cost savings for healthcare providers compared to standard of care*.
- Twice as many chronic wounds healed at 8–16 weeks compared to standard of care*
- Time to heal diabetic foot ulcers 50% shorter than with standard of care*
- Treatment costs in diabetic foot ulcers at least 40% lower than with standard of care
- More than 70% of patients reported lower average pain scores at four weeks than with standard of care in chronic wounds*
- 99% less slough in chronic wounds after 4 weeks compared to 33% with standard of care*
The Prix Galien is an annual prize which recognizes innovative medical devices which improve the human condition. The awards were created in France in 1970 by pharmacist Roland Mehl, in honour of Galen, the father of medical science and modern pharmacology. Receiving a Prix Galien is the highest accolade for the world’s most innovative medicines and devices and is considered the pharmaceutical and medical industry’s equivalent of the Nobel prize.
In their summation, the Prix Galien jury highlighted Mölnlycke’s impressive dossier, video and clinical results. They commented that Granulox is used to treat a condition which presents a significant patient burden. It improves quality of life and contributes to interdisciplinary care, which will be important for the healthcare system of the future. Some members of the jury even described it as ‘ingenious’!
CEO Zlatko Rihter says: ‘We’re extremely honoured that Granulox has been recognized by the Prix Galien committee. We’re also humbled to be in such prestigious company alongside businesses like Siemens Healthineers, BeWell Industries, Norgine, and Sunrise. This wouldn’t have been possible without our Belgian team and our Granulox team.’
Rob Claypoole, EVP Global Wound Care said: ‘At Mölnlycke, we’ve long been convinced of the power of Granulox, but that it has now been recognized by the Nobel Prize for medical devices is further proof of just how innovative a product it is. We look forward to helping even more people – whether patients, caregivers, or clinicians -- see the difference topical oxygen therapy can make in wound care.’
Sabrina Suetens, Mölnlycke Business Director for Wound Care & General Manager for Benelux commented, ‘I'm so incredibly proud of the entire team, and we really appreciate this award. The greatest reward, however, is the opportunity to make a difference in chronic wound patients' lives with such an easy-to-use product.’
*References: www.molnlycke.com/products-solutions/granulox/
Anders Hestner, Global Marketing Director Acute Wound Care
anders.hestner@molnlycke.com
Frida Wilhelmsson Ulfbratt, Global Communications Director
frida.wilhelmsson@molnlycke.com
Tags:
